Otsuka subsidiary Taiho Pharmaceuticals earlier announced that the results of a Phase III, randomized, placebo-controlled, ...

Shares of US clinical-stage biotech Apogee Therapeutics closed down 17.3% at $39.24 yesterday, despite announcing positive 16 ...

French biotech Nanobiotix’ (shares were up nearly 7% at 4.44 euros in early trading, after the company announced two important developments that aim to reinforce the global positioning of potential ...

Eli Lilly (NYSE: LLY) led the way in pharma M&A during June. The US pharma major announced two major deals in the month, both ...

Actinogen Medical (ASX: ACW), an Australian biotech, announced that the 100th participant in its pivotal XanaMIA Phase ...

The GPRC5D-directed therapies market is witnessing robust growth, driven by high unmet need in relapsed/refractory multiple ...

Japan’s Nxera Pharma is to receive a $4.8 million milestone payment from UK pharma company Centessa Pharmaceuticals as part of the firms’ research collaboration.

Japanese drugmaker Chugai Pharmaceutical has entered into a joint research and license agreement to develop novel therapies for age-related diseases with Singapore-based biotech Gero.

USA and UK-based KalVista Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Ekterly (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of ...

A nasal COVID-19 vaccine developed by US biotech CyanVac has produced encouraging results in an early trial, showing potential to offer broader immunity and easier delivery than current injections.